Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RNA vs ODV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ODV Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

ODV Overall Winner 6-Pillar Tally: RNA 2 – 3 ODV (1 Tie) Matrix Metrics: RNA 2 – 8 ODV

As of Nov 16, 2026, Osisko Development Corp. (ODV) is the stronger overall head-to-head candidate over Avidity Biosciences, Inc. (RNA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). RNA carries a Unified Composite Score of 41.9/100 (SELL) at $6.43 (N/M Forward P/E, -194.8% operating margin), whereas ODV carries 56.2/100 (HOLD) at $2.27 (24.0x Forward P/E, -414.1% operating margin).

  • Technical & Structure Timing Caution: RNA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.5); meanwhile ODV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RNA vs ODV
RNA NASDAQ
Avidity Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$6.43
-14.38% 1D
Market Cap $162.0M
TTM Revenue $39M
Forward P/E N/M
Beta / 30D Vol 1.04β · 55% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 16.0 Fund 44.0 Flow 61.0 Mom 65.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.8%), weak momentum, RSI 23
RSI-14: 22.5 · SMA20: $8.11 · SMA50: $8.49
ODV NYSE Head-to-Head Winner
Osisko Development Corp.
Gold And Silver Ores
$2.27
+0.89% 1D
Market Cap $678.0M
TTM Revenue $38M
Forward P/E 24.0x
Beta / 30D Vol 2.13β · 45% Vol
Unified Composite Score
56.2 / 100 HOLD
Tech 25.0 Fund 45.0 Flow 50.0 Mom 68.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $2.44 · SMA50: $2.68

6-Pillar Scorecard Institutional Category Breakdown (RNA 2 – 3 ODV)

Columns: Metric · RNA · ODV
1. Valuation Multiples ODV
Forward P/E N/M 24.0x
Trailing P/E N/M 24.0x
PEG Ratio N/M N/M
EV / Revenue N/M 18.0x
2. Growth & Scale ODV
Revenue Growth (YoY) +24.2% +2638.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $39M $38M
Market Cap $162.0M $678.0M
3. Profitability & Quality RNA
Gross Margin -14.0% 61.5%
Operating Margin -194.8% -414.1%
Net Profit Margin -180.9% -189.6%
Return on Equity (ROE) -95.0% -12.4%
4. Balance Sheet & Cash Flow ODV
Cash Generation (TTM) -$73M -$43M EBITDA
Cash Flow Margin N/A -114.9% EBITDA Mgn
Net Cash / Leverage $265M Net Cash $2.29 Book/Sh · -12.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RNA
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 0.9% (2nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Gold Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RNA (2) vs ODV (8)
Institutional Metric RNA ODV Criterion Row Edge
Market Capitalization
Scale
$162.0M $678.0M Larger Scale ODV
Trailing P/E Ratio
Valuation
N/M 24.0x Lower Multiple ODV
Forward P/E Ratio
Valuation
N/M 24.0x Lower Multiple ODV
Revenue Growth (YoY)
Growth
+24.2% +2638.5% Higher Growth ODV
Operating Margin (TTM)
Profitability
-194.8% -414.1% Higher Margin RNA
Net Profit Margin
Profitability
-180.9% -189.6% Higher Margin RNA
Return on Equity (ROE)
Capital Efficiency
-95.0% -12.4% Higher ROE ODV
52-Week Range Position
Momentum
0% ($6–$73) 5% ($2–$5) Stronger Trend ODV
Beta / 30D Volatility
Risk Regime
1.04β · 55% Vol 2.13β · 45% Vol Lower Realized Risk ODV
Unified Institutional Score
Composite Signal
41.9 / 100 (SELL) 56.2 / 100 (HOLD) Higher Composite ODV
Trailing 12M Revenue (USD)
Operating Scale
$39M $38M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-14.0% 61.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 18.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$73M ($265M Net Cash) -$43M EBITDA ($2.29 Book/Sh · -12.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RNA +14.7 pp
RNA: -3.65% · ODV: -18.35%
3M Horizon RNA +19.24 pp
RNA: -13.4% · ODV: -32.64%
6M Horizon ODV +45.76 pp
RNA: -83.23% · ODV: -37.47%
1Y Horizon ODV +49.02 pp
RNA: -82.84% · ODV: -33.82%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RNA vs ODV. Trailing 12-month operating profitability (RNA -194.8% vs ODV -414.1%) and valuation multiples (RNA N/M vs ODV 24.0x Forward P/E) are benchmarked directly in Pillar 4 below.

RNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-14.0%
Op. Margin-194.8%
ROE / Fwd P/E-95.0% · N/M
ODV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$38M
Gross Margin61.5%
Op. Margin-414.1%
ROE / Fwd P/E-12.4% · 24.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RNA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.9%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ODV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ODV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $162.0M market capitalization and -194.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ODV Moat Profile Cyclical / Execution-Driven Positioning
Gold Operator
Competes within the Gold value chain with $678.0M market capitalization and -414.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RNA vs ODV Key Questions & Quantitative Answers

As of Nov 16, 2026, Osisko Development Corp. (ODV) is the stronger overall head-to-head candidate over Avidity Biosciences, Inc. (RNA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). RNA carries a Unified Composite Score of 41.9/100 (SELL) at $6.43 (N/M Forward P/E, -194.8% operating margin), whereas ODV carries 56.2/100 (HOLD) at $2.27 (24.0x Forward P/E, -414.1% operating margin). Technical & Structure Timing Caution: RNA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.5); meanwhile ODV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ODV leads the Growth & Scale pillar: RNA posts +24.2% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-14.0% gross margin, -194.8% operating margin), compared with ODV at +2638.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (61.5% gross margin, -414.1% operating margin). On trailing 12-month operating scale, RNA generates $39M in USD-normalized revenue versus $38M for ODV. In operating R&D and SG&A reinvestment, RNA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ODV.

ODV screens cheaper on headline valuation multiples. RNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ODV trades at 24.0x Forward P/E, 24.0x Trailing P/E, N/M PEG, and 18.0x EV/Revenue (-114.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RNA (-95.0% ROE) versus ODV (-12.4% ROE) capital efficiency.

In options market volatility and institutional positioning, RNA carries 0.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 55% Vol realized risk). By comparison, ODV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.13β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.